Healthcare
Eisai Co., Ltd.(ESAIY)
Live Price
Offline$6.10
+3.39% today
Window Change
-20.69%
Window
May 6, 2026 → Jun 24, 2026
- Market Cap
- $1.32T
- Revenue Growth
- +6.4%
- EPS Growth
- +10.8%
- Dividend Yield
- 3.4%
Historical coverage is still filling in
This 1Y daily history view is currently sparse. Use it as directional context while we continue backfilling more history.
Coverage: 34 bars · May 6, 2026 → Jun 24, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Eisai Co., Ltd. (ESAIY) is a Healthcare stock with a market cap of $1.32T and listed on OTC. The stock last traded around $6.10 and down 20.7% across the available one-year price window (May 6, 2026 → Jun 24, 2026). Baseline metrics include revenue growth of +6.4%, EPS growth of +10.8%, a dividend yield of 3.4%. What stands out right now is revenue +6.4%, EPS +10.8%, free cash flow -77.1% with operating margin 5.6% and ROIC 2.8%. The dividend matters to the case here, with a current yield around 3.4%. Valuation already assumes a fairly strong business story at P/E 30.9 and price/sales 1.6. Stock Foundry combines ESAIY price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Near sector median
+6.4% vs +7.6% peer median
Operating Margin
Below sector median
+5.6% vs +19.4% peer median
P/E
Below sector median
30.9 vs 36.3 peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
The operating story is still moving forward
Revenue is running at +6.4% and EPS at +10.8%, with operating margin around 5.6%.
Shareholder return is still part of the story
The stock is still offering a dividend yield around 3.4%, which matters if the thesis depends on income as much as growth.
Benchmark Edge
ESAIY vs SPY, QQQ, and Sector ETFs
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
ESAIY
—
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
ESAIY Max Drawdown
-24.27%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for ESAIY and SPY.
Company Overview
Eisai Co., Ltd.
Other OTC
Eisai Co., Ltd. engages in the research and development, manufacture, sale, and import and export of pharmaceuticals in Japan. It offers Dayvigo, for the treatment of insomnia; Lenvima, an anticancer agent/molecular targeted medicine for the treatment of thyroid cancer, renal cell carcinoma in combination with everolimus, and hepatocellular carcinoma; Methycobal for the treatment of peripheral neuropathy; and Halaven, an anticancer agent for the treatment of breast cancer. The company also provides Jyseleca, a janus kinase inhibitor; Elental, a branched-chain amino acid preparation; Goofice and Movicol for chronic constipation; Fycompa, an antiepileptic agent; Pariet, a proton-pump inhibitor; Aricept, for Alzheimer's disease/Dementia with Lewy bodies; and Chocola BB plus for the preparation vitamin B2. It has strategic collaboration with Bristol Myers Squibb for the co-development and co-commercialization of farletuzumab ecteribulin antibody drug conjugate. Eisai Co., Ltd. was formerly known as Nihon Eisai Co., Ltd. and changed its name to Eisai Co., Ltd. in 1955. Eisai Co., Ltd. was incorporated in 1941 and is headquartered in Tokyo, Japan.
- Leadership
- Haruo Naito
- IPO Date
- Feb 2, 2023
- Employees
- 11.1k
- Street Address
- 4-6-10, Koishikawa
- Mailing
- Tokyo, 112-8088
- Region
- Tokyo, JP
- Reporting Currency
- USD
- Investor Line
- 81 3 3817 3700
- Last Updated
- Apr 28, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- 30.9
- EV/EBITDA
- 13.8
- Price/Sales
- 1.6
- Price/Book
- 1.5
Growth
- Revenue
- +6.4%
- EPS
- +10.8%
- Free Cash Flow
- -77.1%
Profitability
- Gross Margin
- 77.8%
- Operating Margin
- 5.6%
- Net Margin
- 5.3%
- ROE
- 5.0%
- ROIC
- 2.8%
Balance Sheet
- Debt/Equity
- 0.26
- Current Ratio
- 2.17
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.